Author(s)

Bode Easaw

Affiliation(s)

Adis International Limited, Mairangi Bay, Auckland 10, New Zealand.

Corresponding Author

Bode Easaw

ABSTRACT

Coronary heart disease, as one of the common heart diseases, is also called coronary atherosclerotic heart disease. It is specifically characterized by myocardial ischemia or hypoxia caused by coronary atherosclerosis or dynamic vasospasm in patients. Myocardial necrosis and other conditions can cause patients to suffer from myocardial infarction, death, angina and other diseases. However, with the accelerated pace of people's life and unreasonable dietary structure, coronary heart disease appears in people of all ages, which can easily induce various cardiovascular and cerebrovascular complications and seriously threaten the life, health and safety of patients. This needs to be strengthened. Clinical trials of effective drugs for coronary heart disease to enhance the therapeutic effect of coronary heart disease.

KEYWORDS

Nicorandil; Coronary heart disease; Clinical treatment progress; Evaluation

CITE THIS PAPER

Bode Easaw. Assessment of the therapeutic effectiveness of Nicorandil in the management of coronary heart disease. Journal of Pharmaceutical and Medical Research. 2024, 6(2): 6-7. DOI: 10.61784/jpmrv6n217.

REFERENCES

[1] Li Ying. Progress in clinical research of nicorandil in the treatment of coronary heart disease. Chinese Prescription Drugs, 2017, 16(09): 18-20.

[2] Nakamura Y, Akima M, Sakai K. Influence of nicorandil, an antianginal agent, on the therapeutic and toxic cardiovascular actions of ouabain in the anaesthetised dog. Clinical and Experimental Pharmacology and Physiology. 1984, 11: 275–283.

[3] Wang Xue. Evaluation of the clinical efficacy of nicorandil in the treatment of angina pectoris in patients with coronary heart disease after interventional therapy. Chinese Medical Guide, 2016, 16(28): 55-56.

[4] Shvartsur R, Shiyovich A, Gilutz H, Azab AN, Plakht Y. Short and long-term prognosis following acute myocardial infarction according to the country of origin. Soroka acute myocardial infarction II (SAMI II) project. Int J Cardiol. 2018, 259:227–233. doi:10.1016/j.ijcard.2018.02.07929499852.

[5] Liu Yongquan, Liu Ning. Progress in the clinical application of nicorandil in the treatment of coronary heart disease. Journal of Clinical and Experimental Medicine, 2017, 8(09): 132-133.

[6] Tarkin JM, Kaski JC. Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris. Eur Cardiol. 2018,13(1):23–28. doi:10.15420/ecr.2018.9.230310466.

[7] Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999, 33(3):654–660.10080465.